These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inflammation: a unifying theory for the origin of dry eye syndrome. Wilson SE Manag Care; 2003 Dec; 12(12 Suppl):14-9. PubMed ID: 14723109 [TBL] [Abstract][Full Text] [Related]
5. Considerations in the pharmacoeconomics of dry eye. Hirsch JD Manag Care; 2003 Dec; 12(12 Suppl):33-8. PubMed ID: 14723112 [TBL] [Abstract][Full Text] [Related]
6. Medications for dry eye syndrome: a drug-therapy review. Perry HD; Donnenfeld ED Manag Care; 2003 Dec; 12(12 Suppl):26-32. PubMed ID: 14723111 [TBL] [Abstract][Full Text] [Related]
7. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Trattler W; Katsev D; Kerney D Clin Ther; 2006 Nov; 28(11):1848-56. PubMed ID: 17213005 [TBL] [Abstract][Full Text] [Related]
8. Guidelines for the treatment of chronic dry eye disease. Sheppard JD Manag Care; 2003 Dec; 12(12 Suppl):20-5. PubMed ID: 14723110 [TBL] [Abstract][Full Text] [Related]
9. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500 [TBL] [Abstract][Full Text] [Related]
10. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211 [TBL] [Abstract][Full Text] [Related]
11. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Cordero-Coma M; Anzaar F; Sobrin L; Foster CS Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834 [TBL] [Abstract][Full Text] [Related]
12. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drugs Ther; 2003 May; 45(1157):42-3. PubMed ID: 12766701 [No Abstract] [Full Text] [Related]
13. Clinically important difference in dry eye: change in IDEEL-symptom bother. Fairchild CJ; Chalmers RL; Begley CG Optom Vis Sci; 2008 Aug; 85(8):699-707. PubMed ID: 18677226 [TBL] [Abstract][Full Text] [Related]
14. [Dry eye syndrome in rheumatoid arthritis patients]. Polanská V; Hlinomazová Z; Fojtík Z; Nemec P Cesk Slov Oftalmol; 2007 Nov; 63(6):422-30. PubMed ID: 18062166 [TBL] [Abstract][Full Text] [Related]
15. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Stonecipher K; Perry HD; Gross RH; Kerney DL Curr Med Res Opin; 2005 Jul; 21(7):1057-63. PubMed ID: 16004673 [TBL] [Abstract][Full Text] [Related]
16. Responses to a dry eye questionnaire from a normal population. McMonnies CW; Ho A J Am Optom Assoc; 1987 Jul; 58(7):588-91. PubMed ID: 3668156 [TBL] [Abstract][Full Text] [Related]
17. Dry eye symptoms following cataract surgery. Roberts CW; Elie ER Insight; 2007; 32(1):14-21; quiz 22-3. PubMed ID: 17533782 [TBL] [Abstract][Full Text] [Related]
18. Understanding dry eye disease: a managed care perspective. Fiscella RG Am J Manag Care; 2011 Dec; 17 Suppl 16():S432-9. PubMed ID: 22435675 [TBL] [Abstract][Full Text] [Related]
19. Keratoconjunctivitis sicca modifies epithelial stem cell proliferation kinetics in conjunctiva. Chen W; Zhao K; Li X; Yoshitomi T Cornea; 2007 Oct; 26(9):1101-6. PubMed ID: 17893543 [TBL] [Abstract][Full Text] [Related]
20. [Effect of anti-inflammatory therapy on the treatment of dry eye syndrome]. Mrukwa-Kominek E; Rogowska-Godela A; Gierek-Ciaciura S Klin Oczna; 2007; 109(1-3):79-84. PubMed ID: 17687921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]